Companies Dominating the BCL-2 (B-cell lymphoma 2) Inhibitors Market
- Abcam plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Amgen Inc.
- Ascentage Pharma Group International
- Seagen Inc.
- Servier
- AbbVie Inc.
- F. Hoffmann La Roche Ltd.
- Ipsen Pharma
- Merck and Co. Inc.
- Novartis AG
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of BCL-2 inhibitors is estimated at USD 2.55 billion.
The BCL-2 inhibitors market size was valued at USD 2.28 billion in 2024 and is likely to cross USD 12.67 billion by 2037, registering more than 14.1% CAGR during the forecast period i.e., between 2025-2037. Rising cases of Diffuse B-cell Lymphoma and growing government initiatives will drive the market growth.
North America industry is poised to account for largest revenue share of 56% by 2037, impelled by increasing product approvals in the region.
The major players in the market are Amgen Inc., Ascentage Pharma Group International, AstraZeneca Plc, Seagen Inc., Servier, AbbVie Inc., F. Hoffmann La Roche Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG.
